课题基金 / 基金详情

Multi-Modal Venus Clot Removal Device

Multi-Modal Venus Clot Removal Device
多模式维纳斯凝块去除装置
批准号:
10009791
负责人:
Mohamed A. Zayed
金额:
$19.41万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-01 至 2021-08-31

项目摘要

项目成果

Mohamed A. Zayed的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 凯利血管有限责任公司的这项第一阶段STTR应用需要12个月的时间,重点是 一种新型血管内静脉取栓装置的研制少年派是一名血管外科医生, 具有生物医学研究和创业经验,并由一支高素质的团队提供支持 调查人员,包括一名血管生物学家,神经外科医生,兽医,生物医学工程师,机械 工程师,以及营销和管理专家。此应用程序的主要目标是测试 基于导管的静脉血栓摘除装置设计,旨在解决目前技术水平上的所有空白 下腔静脉和髂静脉大容量深静脉血栓的治疗 静脉段)。 每年,超过90万美国人会患上大量的深静脉血栓。多达100,000人将死于 在确诊后2周内出现并发症。约50%的大容量急性胰腺炎患者 深静脉血栓会发展成严重的并发症,如致命性肺血栓(PE)。大块头的治疗选择 髂腔静脉段的DVT容量有限,目前可经皮血管内治疗 血栓消融器有各种缺点,影响了治疗的有效性和安全性。主要差距包括 术中血栓栓塞术导致PE风险增加,溶栓穿透性差导致 增加出血风险,以及无法完全清除血栓导致DVT未解决。致信地址 我们设计和制作的经皮静脉取栓装置的所有技术水平的空白 九头蛇导管。Hydra导管的独特和专有功能包括可调节的包裹体 气囊,便于输送溶栓剂和等容输液/抽吸的输液导管段, 还有一个内置的传单搅拌器。我们的初步研究结果显示,与目前的FDA相比,我们的疗效更高- 批准的机械抽吸取栓导管。我们的多学科调查团队建议 在体外腔静脉血流模型中测试Hydra导管原型在以下临床应用中的可行性: 相关具体目标: 目的一:证实九头蛇导管可调球囊封堵设计可消除血栓形成 远端血栓碎片。 目的II:证明等容抽吸术可以清除静脉‘治疗区’而不会有静脉风险 墙体坍塌和膨胀损坏。 目的III:确定Hydra导管小叶搅拌器是否增加血块的碎裂和抓取。 通过完成这些提议的目标,我们将确定新型九头蛇导管的机械可行性 治疗大容量髂腔深静脉血栓的原型。这些发现将使我们能够准备第二阶段之前的 通过预期的510(K)机制获得FDA监管批准所需的商业化研究 基于为机械或化学血栓清除术设计的断言装置。
英文摘要
ABSTRACT This Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, mechanical engineer, and a marketing and management expert. The primary objective of this application is to test a catheter-based venous thrombectomy device designed to address all current gaps in the state of the art for the treatment of large volume deep venous thrombus (DVT) in the inferior vena cava (IVC) and iliac veins (iliocaval venous segment). Each year, more than 900,000 Americans will develop a large-volume DVT. As many as 100,000 will die as a result of a complication within 2 weeks of diagnosis. Approximately 50% of patients with large-volume acute DVT will develop a severe complication such as fatal pulmonary emboli (PE). Treatment options of large volume DVT in the iliocaval venous segment are limited, and currently available percutaneous endovascular thrombectomy devices have various shortcomings that affect treatment efficacy and safety. Major gaps include increased risk of intra-procedural thrombus embolization leading to PE, poor thrombolytic penetration leading to increased bleeding risk, and inability to completely remove thrombus leading to unresolved DVT. To address all the gaps in the state of the art of percutaneous venous thrombectomy devices we designed and prototyped the Hydra Catheter. Unique and proprietary features of the Hydra Catheter include adjustable ecapsulation balloons, an infusion catheter segment to facilitate delivery of thrombolytics and isovolumetric infusion/suction, and a built-in leaflet agitator. Our preliminary findings demonstrated high efficacy compared to current FDA- approved mechanical suction thrombectomy catheters. Our multi-disciplinary team of investigators proposes to test feasibility of the Hydra Catheter prototype in an ex vivo vena cava flow model in the following clinically- relevant specific aims: Aim I: Confirm that Hydra catheter adjustable balloon encapsulation design eliminates embolization of distal thrombus fragments. Aim II: Demonstrate that isovolumetric suction can clear a venous ‘treatment zone’ without risk of venous wall collapse and distension damage. Aim III: Determine whether Hydra Catheter leaflet agitator increases blood clot fragmentation and grasping. By completing these proposed aims we will establish the mechanical feasibility of the novel Hydra catheter prototype for the treatment of large-volume iliocaval DVT. These findings will allow us to prepare Phase II pre- commercialization studies necessary for FDA-regulatory clearance through an anticipated 510(k) mechanism based on predicate devices designed for either mechanical or chemical thrombectomy.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Quantification of the flexural rigidity of endovascular surgical devices using three-point bending tests.
使用三点弯曲测试量化血管内手术装置的弯曲刚度。
DOI: 10.21203/rs.3.rs-3736325/v1
发表时间: 2023
期刊: Research square
影响因子: --
作者: [Qiu,MichaelY, Suskin,CharlesB, Becerra-Garcia,JuanJ, Roberts,SophiaH, Rucker,DeVaughnG, Zayed,MohamedA, Osbun,JoshuaW, Genin,GuyM]
通讯作者: Genin,GuyM
DOI: 10.1038/s41598-022-09001-6
发表时间: 2022-03-28
期刊: Scientific reports
影响因子: 4.6
作者: [Ismail U, Rowe RA, Cashin J, Genin GM, Zayed MA]
通讯作者: Zayed MA
DOI: 10.1038/s41598-021-90813-3
发表时间: 2021-06-09
期刊: Scientific reports
影响因子: 4.6
作者: [Williams D, Leuthardt EC, Genin GM, Zayed M]
通讯作者: Zayed M
Regulation of Endothelial Lipid Metabolism in the Setting of Diabetes and Critical Limb Ischemia to Prevent Surgical Complications
  • 批准号:
    10375540
  • 项目类别:
  • 资助金额:
    $52.55万
  • 财政年份:
    2021
  • 负责人:
    Mohamed A. Zayed
  • 依托单位:
Regulation of Endothelial Lipid Metabolism in the Setting of Diabetes and Critical Limb Ischemia to Prevent Surgical Complications
  • 批准号:
    10586058
  • 项目类别:
  • 资助金额:
    $52.55万
  • 财政年份:
    2021
  • 负责人:
    Mohamed A. Zayed
  • 依托单位:
Regulation of Endothelial Lipid Metabolism in the Setting of Diabetes and Critical Limb Ischemia to Prevent Surgical Complications
  • 批准号:
    10209164
  • 项目类别:
  • 资助金额:
    $55.64万
  • 财政年份:
    2021
  • 负责人:
    Mohamed A. Zayed
  • 依托单位:
海外基金